Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting

This study has been terminated.
(The study was stopped for financial reasons)
Sponsor:
Information provided by (Responsible Party):
Theratechnologies
ClinicalTrials.gov Identifier:
NCT01388920
First received: July 5, 2011
Last updated: November 25, 2013
Last verified: November 2013
  Purpose

A significant proportion of COPD subjects experience muscle wasting, which has been associated with increased morbidity, impaired physical functioning, and a poor quality of life.

Muscle wasting is associated with reduced muscle strength in COPD subjects. In particular, weakness of peripheral muscles has been reported to play an important role in the reduced functional capacity and impaired exercise performance.

The primary objective of this study is to investigate the effect of tesamorelin, in conjunction with exercise training, on lean body mass measured by dual energy x-ray absorptiometry (DXA) scan.


Condition Intervention Phase
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Tesamorelin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Doses of Tesamorelin in Stable Ambulatory COPD Subjects With Muscle Wasting

Resource links provided by NLM:


Further study details as provided by Theratechnologies:

Primary Outcome Measures:
  • Lean body mass [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The primary objective of the study is to evaluate the effect of tesamorelin on lean body mass by DXA scan


Secondary Outcome Measures:
  • Exercise capacity [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Peripheral muscle strength [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Patient-reported outcomes [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Adverse events [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    Number and percentage of subjects with adverse events

  • COPD exacerbations [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    Frequency and severity of COPD exacerbations

  • Plasma glucose [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    Changes from baseline in fasting blood glucose


Enrollment: 3
Study Start Date: September 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tesamorelin 2 mg
Tesamorelin 2 mg/day
Drug: Tesamorelin
Experimental: Tesamorelin 3 mg
Tesamorelin 3 mg/day
Drug: Tesamorelin
Placebo Comparator: Placebo

  Eligibility

Ages Eligible for Study:   40 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects aged 40-75 years (y) inclusive
  • Documented diagnosis of moderate to very severe COPD (GOLD stage 2, 3, or 4)
  • Stable COPD (i.e., no exacerbation) for at least 6 weeks prior to screening
  • Able to participate in a supervised exercise training program
  • Evidence of muscle wasting

Exclusion Criteria

  • Participation in a pulmonary rehabilitation program or in any supervised exercise program during the 4 months prior to screening
  • More than 4 exacerbations in the year prior to screening
  • Life-threatening exacerbation in the year prior to screening
  • Requirement for long-term oxygen therapy (> 12 hours of oxygen per day)
  • Critical illness or co-morbid conditions that may interfere with study conduct or endpoint measurements
  • Use of agents known to increase lean body mass within 3 months prior to screening
  • Hypopituitarism, history of pituitary tumor/surgery, head irradiation, or severe head trauma
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01388920

Sponsors and Collaborators
Theratechnologies
Investigators
Principal Investigator: Richard Casaburi, PhD, MD University of California, Los Angeles
  More Information

No publications provided

Responsible Party: Theratechnologies
ClinicalTrials.gov Identifier: NCT01388920     History of Changes
Other Study ID Numbers: TH9507-CTR-1025
Study First Received: July 5, 2011
Last Updated: November 25, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Theratechnologies:
COPD
Muscle wasting

Additional relevant MeSH terms:
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Muscular Atrophy
Lung Diseases, Obstructive
Respiratory Tract Diseases
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Atrophy
Pathological Conditions, Anatomical
Signs and Symptoms
Growth Hormone-Releasing Hormone
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 17, 2014